Denmark-based medical foundation Novo, which invests $300m per year through its corporate venturing funds, has reinvested in US-based drugs company Logical Therapeutics’ in its third round of funding. Logical raised $16.9m in its series C round led by venture capital firms SV Life Sciences (SVLS) and Novitas Capital and including merchant bank and VC Burrill & Company alongside Novo. The four series C investors, along with Sigvion Capital and PA Early Stage Partners, which provided the seed funding for Logical in July 2006, had invested $30m in Logical’s series B round in mid-2007. The biotechnology company is working on anti-inflamatory drugs and last year hired Peter Lankau as its chief executive from listed pharmaceutical company Endo.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?